Glioblastoma

About Glioblastoma

Glioblastoma (GBM) comprises about 16% of all malignancies of the nervous system and over 50% of all gliomas, and is most common in patients >45 years old. The current standard of care for newly-diagnosed GBM is limited to a combination of surgical debulking followed by concurrent radiotherapy and chemotherapy with temozolomide.

High-grade gliomas (HGG) are either World Health Organization (WHO) grade 3 or grade 4 tumors and tend to grow rapidly and spread faster than tumors of a lower grade. The most common grade 3 tumor is anaplastic astrocytoma and the most common grade 4 tumor is GBM.

The mTOR pathway is frequently over activated in multiple human malignancies including GBM, however oral rapalogs shown poor brain penetration, limiting their potential use for treating GBM. [2] ABI-009 penetrates the blood-brain barrier and high CNS penetration was observed in preclinical studies. [3]

AADi is currently investigating the safety and efficacy of ABI-009 as single agent and in combination with a number of standard and investigational therapies in patients with recurrent HGG and in combination with temozolomide and radiation after surgery in newly diagnosed GBM in a phase 2 study (NCT03463265).

  1. CBTRUS Statistical Report: Primary Brain and CNS Tumors Diagnosed in the US in 2004 – 2008.
  2. O’Reilly et al., Cancer Chemother Pharmacol 65(4): 625-639.
  3. Aadi data on file.

Glioblastoma

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy